

IDS - 03/23/2006

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, No Person is Required to Respond to a Collection of Information unless it Contains a Valid OMB Control Number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

2

## Complete If Known

Application Number	09/966,724
Filing Date	October 1, 2001
First Named Inventor	Kinzler
Group Art Unit	1635
Examiner Name	Jon Ashen
Attorney Docket Number	001107.00193

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code <sup>2</sup> (if known)		
BW		4,806,463		Goodchild & Zamecnik	12-21-1989
BW		5,004,810		Draper	04-02-1991

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)		

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
BW		Burch & Mahan, "Oligonucleotides Antisense to the Interleukin 1 Receptor mRNA Block the Effects of Interleukin 1 in cultured Murine and Human Fibroblasts and in Mice," <i>J. Clin. Investigation, Inc.</i> 88, 1190-96, October 1991			
		Dagle <i>et al.</i> , "Physical properties of oligonucleotides containing phosphoramidate-modified internucleoside linkages," <i>Nucl. Acids Res.</i> 19, 1805-10, 1991			
		Flood <i>et al.</i> , "Inhibition of Ly-6A Antigen Expression Prevents T Cell Activation," <i>J. Exp. Med.</i> 172, 115-20, July 1990			
		Hambor <i>et al.</i> , "Use of an Epstein-Barr virus Episomal Replicon for anti-sense RNA-mediated gene inhibition in a human cytotoxic T-cell clone," <i>Proc. Natl. Acad. Sci. USA</i> 85, 4010-14, June 1988; see page 4011, col. 1, lines 40-45.			
		Harel-Bellan <i>et al.</i> , "Specific inhibition of c-myc protein biosynthesis using an antisense synthetic deox-oligonucleotide in human T lymphocytes," <i>J. Immunol.</i> 140, 2431-35, April 1988 (abstract)			
		Harel-Bellan <i>et al.</i> , "Specific Inhibition of Lymphokine Biosynthesis and Autocrine Growth Using Antisense Oligonucleotides in Th1 and Th2 Helper T Cell Clones," <i>J. Exp. Med.</i> 168, 2309-18, December 1988			
BW		Morrison, "Suppression of Basic Fibroblast Growth Factor Expression by Antisense Oligodeoxynucleotides Inhibits the Growth of Transformed Human Astrocytes," <i>J. Biol. Chem.</i> 266, 728-34, January 15, 1991			

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0851-0031

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

2 of 2

### Complete If Known

Application Number	09/966,724
Filing Date	October 1, 2001
First Named Inventor	Kinzler
Group Art Unit	1635
Examiner Name	Jon Ashen
Attorney Docket Number	001107.00193

U.S. PATENT DOCUMENTS						
Examiner Initials *	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)		

### OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
BW		Sankar <i>et al.</i> , Antisense oligonucleotide inhibition of encephalomyocarditis virus RNA translation," <i>Eur. J. Biochem.</i> 184, 39-45, September 1989 (abstract)	
		Simons & Rosenberg, "Antisense nonmuscle myosin heavy chain and cmyb oligonucleotides suppress smooth muscle cell proliferation in vitro," <i>Cir. Res.</i> 70, 835-43, April 1992 (abstract)	
		Sumikawa & Miledi, "Repression of nicotinic acetylcholine receptor expression by antisense RNAs and an oligonucleotide," <i>Proc. Natl. Acad. Sci. USA</i> 85, 1302-06, February 1988	
		Ullmann & Peyman, "Antisense Oligonucleotides: A New Therapeutic Principle," <i>Chemical Review</i> 90, 544-84, June 1990	
		Watson <i>et al.</i> , "Inhibition of c-myc expression by phosphorothioate antisense oligonucleotide identifies a critical role for c-myc in the growth of human breast cancer," <i>Cancer Res.</i> 51, 3996-4000, August 1991 (abstract)	
		Woolf <i>et al.</i> , "The stability, toxicity and effectiveness of unmodified and phosphorothioate antisense oligodeoxynucleotides in Xenopus oocytes and embryos," <i>Nucl. Acids Res.</i> 18, 1763-69, 1990	
BW		Zhang <i>et al.</i> , "Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapy," <i>Proc. Natl. Acad. Sci. USA</i> 100, 11636-41, September 30, 2003	

Examiner Signature	/Brian Whiteman/	Date Considered	08/01/2006
--------------------	------------------	-----------------	------------

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0551-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of 2

Complete If Known

Application Number	09/966,724
Filing Date	October 1, 2001
First Named Inventor	Kinzler
Group Art Unit	1635
Examiner Name	Jon Ashen

Attorney Docket Number

001107.00193

### U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
BW		6,238,921		Miraglia et al.	May 29, 2001	

### FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>4</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				

### OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
BW		Bartel et al., "MDM2 and Its Splice Variant Messenger RNAs: Expression in Tumors and Down-Regulation Using Antisense Oligonucleotides," <i>Mol. Cancer Res.</i> 2, 29-35, January 2004	
		Capoulade et al., "Apoptosis of tumoral and nontumoral lymphoid cells is induced by both mdm2 and p53 antisense oligodeoxynucleotides," <i>Blood</i> 97, 1043-49, February 15, 2001	
		Chen et al., "Synergistic activation of p53 by inhibition of MDM2 expression and DNA damage," <i>Proc. Natl. Acad. Sci. USA</i> 95, 195-200, January 1998	
		Fiddler et al., "Amplification of MDM2 Inhibits MyoD-Mediated Myogenesis," <i>Mol. Cell. Biol.</i> 16, 5048-57, September 1996	
		Goetz et al., "Requirement for Mdm2 in the Survival Effects of Bcr-Abl and Interleukin 3 in Hematopoietic Cells," <i>Cancer Res.</i> 61, 7635-41, October 15, 2001	
		Sato et al., "Enhancement of Drug Induced Apoptosis by Antisense Oligodeoxynucleotides Targeted against Mdm2 and p21 <sup>WAF1/CIP1</sup> ," <i>Anticancer Research</i> 20, 837-42, 2000	
		Uhlmann & Peyman, "Antisense Oligonucleotides: A New Therapeutic Principle," <i>Chem Rev.</i> 90, 543-84, 1990	
BW		Wang et al., "MDM2 oncogene as a target for cancer therapy: An antisense approach," <i>Int. J. Oncol.</i> 15, 653-60, 1999	

Examiner Signature		Date Considered
--------------------	--	-----------------

Please type a plus sign (+) inside this box →

FEB 24 2006

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

2 of 2

Complete If Known

Application Number	09/966,724
Filing Date	October 1, 2001
First Named Inventor	Kinzler
Group Art Unit	1635
Examiner Name	Jon Ashen

Attorney Docket Number

001107.00193

### U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
	0,260,921			Miraglia et al.	May 20, 2001	

### FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>3</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				

### OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
BW		Wang et al., "Antisense Anticancer Oligonucleotide Therapeutics," <i>Current Cancer Drug Targets</i> 1, 177-96, 2001	
BW		Wang et al., "Chemosensitization and Radiosensitization of Human Cancer by Antisense Anti-MDM2 Oligonucleotides," <i>Ann. N.Y Acad. Sci.</i> 1002, 217-35, 2003	
BW		Zang & Wang, "Antisense Oligonucleotide Inhibitors of MDM2 Oncogene Expression," in <i>Methods in Molecular Medicine 85: Novel Anticancer Drug Protocols</i> , pages 205-22, Buolamwini & Adjei, eds., Humana Press, 2003	

Examiner Signature

/Brian Whiteman/

Date Considered

08/01/2006